Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

Yang, Jing; Xu, Hui; Guo, Xinli; Zhang, Jing; Ye, Xiaoyang; Yang, Yanping; Ma, Xuelei

doi:10.1038/s41598-018-21093-7

Cited by 57 publications

(67 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al, ; L. Chen et al, ; Conroy et al, ; Feng et al, ; Fu et al, ; Gao et al, ; Y. Geng et al, ; X.R. Geng et al, ; Guo et al, ; Ha et al, ; Hu et al, ; Huang et al, ; X. Liu et al, ; Margetts et al, ; Pang et al, ; Passardi et al, ; K. Wang et al, ; L. Wang et al, ; Z. Yang et al, ; J. Yang et al, ; J. Yang et al, ; W.J. Zhou et al, ), including 25 cohort studies and, in total, 9,626 cases were finally included.…”

Section: Resultsmentioning

confidence: 99%

Prognostic value of pretreatment systemic immune‐inflammation index in patients with gastrointestinal cancers

Zhang

Lin

Yang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

Background: Numerous studies have reported the relationship between systemic immune-inflammation index (SII) and prognosis in gastrointestinal (GI) cancers, but no consensus has been reached. We aimed to systematically evaluate the prognostic value of SII in patients with GI cancers.Methods: Relevant published papers regarding the prognostic value of SII in patients with GI cancers were obtained from a number of electronic databases. The overall hazard ratios and the corresponding 95% confidence intervals (95% CIs) were calculated using a fixed or random effects model to assess the relationship between SII and prognosis through Stata SE 12.0.Results: A total of 24 eligible published articles with 9,626 patients were included.From the pooled results, we found that high SII indicated worse overall survival (OS) in patients with GI cancers (HR = 1.52, 95%CI: 1.29-1.74). And patients with high SII had poorer disease-free survival (HR: 2.28, 95% CI: 1.46-3.10), time to recurrence (HR: 1.70, 95% CI: 1.11-2.30), and recurrence-free survival (HR: 1.60, 95% CI:1.19-2.00) when compared with those with low SII values.Conclusions: SII might serve as a noninvasive and powerful tool for predicting survival outcome in patients with GI cancers. K E Y W O R D SGastrointestinal (GI) cancer, meta-analysis, prognosis, systemic immune-inflammation index (SII)

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic value of pretreatment systemic immune‐inflammation index in patients with gastrointestinal cancers

Zhang

Lin

Yang

et al. 2018

Journal Cellular Physiology

View full text Add to dashboard Cite

show abstract

“…After the acute inflammatory reaction comes a longer period of immunosuppression and overall, the local and systemic changes that follow the surgical intervention, fuel the growth and migration of residual cancer cells, as well as the formation of metastases in distant organs …”

Section: Introductionmentioning

confidence: 99%

Premetastatic niches, exosomes and circulating tumor cells: Early mechanisms of tumor dissemination and the relation to surgery

Raskov

Orhan

Salanti

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

The physiological stress response to surgery promotes wound healing and functional recovery and includes the activation of neural, inflammatory and proangiogenic signaling pathways. Paradoxically, the same pathways also promote metastatic spread and growth of residual cancer. Human and animal studies show that cancer surgery can increase survival, migration and proliferation of residual tumor cells. To secure the survival and growth of disseminated tumor cells, the formation of premetastatic niches in target organs involves a complex interplay between microenvironment, immune system, circulating tumor cells, as well as chemical mediators and exosomes secreted by the primary tumor. This review describes the current understanding of the early mechanisms of dissemination, as well as how surgery may facilitate disease progression.

show abstract

“…SII has been preliminarily investigated in CRC patients, Chen et al was the first to establish the advantage prognostic value of SII than NLR and PLR in patients with CRC after radical surgery [ 30 ]. Passardi et al and Yang et al also confirmed the prognostic value of SII, however, SII didn’t show advantage than PLR and NLR [ 31 , 32 ], and not as NLR able to predict the efficacy of bevacizumab in mCRC [ 32 ]. However, these studies [ 30 – 32 ] were restricted by the limited information on pathologic features and treatment regimen.…”

Section: Introductionmentioning

confidence: 99%

The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor

Xie

Chen

et al. 2018

J Transl Med

View full text Add to dashboard Cite

BackgroundSystemic inflammation and immune dysfunction has been proved to be significantly associated with cancer progression and metastasis in many cancer types, including colorectal cancer. We examined the prognostic significance of the systemic immune-inflammation index (SII) in patients with metastatic colorectal cancer (mCRC) and the relationship between the lymphocytic response to the tumor and this index.MethodsThis retrospective study evaluated 240 consecutive patients with newly diagnosed stage IV mCRC who underwent surgical resection. The SII values were calculated based on preoperative laboratory data regarding platelet, neutrophil, and lymphocyte counts. Tumor-infiltrating lymphocytes were evaluated using the surgical specimens. The overall survival and their 95% confidence interval (95% CI) were estimated by regression analyses and the Kaplan–Meier method.ResultsAfter a mean follow-up of 26.7 (1.1–92.4) months, 146 patients (60.8%) died. In the univariate analysis, a high SII was significantly associated with poor overall survival (P = 0.009). The multivariable analysis also confirmed that a high SII was independently associated with poor overall survival (hazard ratio: 1.462, 95% confidence interval 1.049–2.038, P = 0.025). The SII value was significantly correlated with the TILs value at the tumor’s center (P = 0.04), but not at the invasive margin (P = 0.39). When we evaluated overall survival for groupings of the tumor-infiltrating lymphocytes and SII values, we identified three distinct prognostic groups. The group with low tumor-infiltrating lymphocyte values and high SII values had the worst prognosis.ConclusionsA high SII value independently predicts poor clinical outcomes among patients with mCRC. In addition, combining the lymphocytic response to the tumor and SII could further enhance prognostication for mCRC.Electronic supplementary materialThe online version of this article (10.1186/s12967-018-1638-9) contains supplementary material, which is available to authorized users.

show abstract

Pretreatment Inflammatory Indexes as Prognostic Predictors for Survival in Colorectal Cancer Patients Receiving Neoadjuvant Chemoradiotherapy

Cited by 57 publications

References 43 publications

Prognostic value of pretreatment systemic immune‐inflammation index in patients with gastrointestinal cancers

Prognostic value of pretreatment systemic immune‐inflammation index in patients with gastrointestinal cancers

Premetastatic niches, exosomes and circulating tumor cells: Early mechanisms of tumor dissemination and the relation to surgery

The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor

Contact Info

Product

Resources

About